2篇
您的检索式：作者名="Vijay L.Kumar"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 幽门螺杆菌根除治疗对非酒精性脂肪肝病患者肝脂肪变化的影响:一项随机对照先导研究显示文摘背景:幽门螺杆菌(Hp)感染可导致胰岛素抵抗和非酒精性脂肪肝病(NAFLD)。本研究旨在评估Hp根除治疗(HPET)与标准治疗(SMT)对NAFLD患者的影响。方法:80例伴有Hp感染的NAFLD患者随机分入SMT组(36例,饮食和锻炼)和HPET组(44例,除饮食和锻炼标准治疗外,予以阿莫西林+克拉红霉素+泮托拉唑三联疗法对Hp进行根除治疗)。检测受控衰减参数(CAP)、体脂参数、肝酶、血脂及包括稳态模型胰岛素抵抗指数(HOMA-IR)在内的血糖参数,比较治疗前及治疗后24周两组患者上述指标的差异。结果:64例患者纳入改良意向性分析,其中SMT组28例,HPET组36例。治疗后24周,SMT组和HPET组患者CAP评分均显著下降(P=0.002和P<0.001),但CAP变化值两组差异无统计学意义(P=0.213)。24周时,HPET组有68%的患者成功根除Hp,与治疗无应答者及SMT组患者相比,Hp根除者HOMA-IR显著改善(P=0.007)。治疗后24周,两组患者肝酶水平均显著下降,但变化值两组差异无统计学意义;血脂水平在治疗前后无显著改变,且两组间差异亦无统计学意义。HPET组患者谷胱甘肽显著下降,但变化值两组差异无统计学意义。结论:与标准治疗相比,辅以Hp根除治疗并不能进一步减轻NAFLD患者的肝脂肪变性和进一步降低肝酶水平,但成功根除Hp可以使HOMA-IR获得显著改善(临床注册号:CTRI/2017/05/008608)。 | Vikas Maharshi Pooja Gupta Vijay L.Kumar Ashish Datt Upadhyay Prasenjit Das Rajni Yadav Baibaswata Nayak Ramesh Kumar Shalimar | 2020 | Gastroenterology Report2020，8，2： | 1 |
| 2 | Antimalarial drug artesunate affords protection against carrageenan induced acute inflammation in rat显示文摘Artesunate, an antimalarial drug, has been shown to inhibit the release of inflammatory mediators in various disease conditions. The present study was carried out to evaluate the anti-edematogenic effect of arte- sunate in the rat paw edema model. Inflammation was induced in the hind paw of rat by sub-plantar injection of 0.1 mL of 0.5% carrageenan and the paw volume was measured up to a fixed mark just before the injection and then after 3 h. The difference in two volumes gave a measure of edema formation. At 3h the level of TNF-α, PGE_(2) and myeloperoxidase were estimated in the inflamed paw tissue. Treatment of rats with single dose of artesunate at 50 and 150 mg/kg produced a dose-dependent inhibition in paw inflammation where a significant reduction in edema volume and mediator release was observed. Our study shows that by inhibiting the release of inflam- matory mediators artesunate affords protection against acute inflammation induced in the rat paw and suggests that it has a potential to be used in the treatment of inflammatory disease conditions. | Vijay L.KUMAR B.GURUPRASAD Priyanka CHAUDHARY | 2014 | BIOCELL2014，38，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员